Ionis Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	943.71	705.14	787.65	587.37	810.46
Revenue Growth (YoY)	33.83%	-10.47%	34.10%	-27.53%	11.13%
Cost of Revenue	931.53	912.75	908.76	847.26	654.3
Gross Profit	12.18	-207.61	-121.11	-259.9	156.16
Selling, General & Admin	393.87	267.47	232.62	150.3	186.35
Operating Expenses	393.87	267.47	232.62	150.3	186.35
Operating Income	-381.68	-475.08	-353.73	-410.19	-30.19
Interest Expense	-90.54	-90.45	-81.46	-8.12	-9.35
Interest & Investment Income	97.77	107.02	89.04	25.33	10.04
Other Non Operating Income (Expenses)	-15.36	1.33	0.71	-7.27	-1.13
EBT Excluding Unusual Items	-389.82	-457.18	-345.44	-400.26	-30.62
Gain (Loss) on Sale of Investments	10.22	-2.89	-1.91	-7.33	10.1
Gain (Loss) on Sale of Assets	-	-	-	149.6	-
Other Unusual Items	-	-	13.39	-	-8.63
Pretax Income	-379.6	-460.07	-333.97	-257.99	-29.15
Income Tax Expense	1.79	-6.17	32.32	11.74	-0.55
Earnings From Continuing Operations	-381.39	-453.9	-366.29	-269.72	-28.6
Net Income	-381.39	-453.9	-366.29	-269.72	-28.6
Net Income to Common	-381.39	-453.9	-366.29	-269.72	-28.6
Shares Outstanding (Basic)	160	150	143	142	141
Shares Outstanding (Diluted)	160	150	143	142	141
Shares Change (YoY)	7.02%	4.42%	0.95%	0.59%	1.01%
EPS (Basic)	-2.38	-3.04	-2.56	-1.90	-0.20
EPS (Diluted)	-2.38	-3.04	-2.56	-1.90	-0.20
Free Cash Flow	-320.03	-546.23	-331.32	-290.09	18.84
Free Cash Flow Per Share	-2.00	-3.65	-2.31	-2.04	0.13
Gross Margin	1.29%	-29.44%	-15.38%	-44.25%	19.27%
Operating Margin	-40.45%	-67.37%	-44.91%	-69.84%	-3.72%
Profit Margin	-40.41%	-64.37%	-46.50%	-45.92%	-3.53%
Free Cash Flow Margin	-33.91%	-77.46%	-42.06%	-49.39%	2.33%
EBITDA	-369.24	-463.13	-340.88	-393.45	-12.35
EBITDA Margin	-39.13%	-65.68%	-43.28%	-66.98%	-1.52%
D&A For EBITDA	12.45	11.95	12.85	16.74	17.84
EBIT	-381.68	-475.08	-353.73	-410.19	-30.19
EBIT Margin	-40.45%	-67.37%	-44.91%	-69.84%	-3.72%
Revenue as Reported	943.71	705.14	787.65	587.37	810.46

Updated Feb 25, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q